本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东凯普生物科技股份有限公司（以下简称"公司"）已于2023年4月15日披 露了《2022年年度报告》及其摘要。为了更好地与广大投资者进行交流，使投资 者能够进一步了解公司2022年度经营情况，公司将于2023年4月20日（星期四） 15:00—17:00在全景网举行2022年度业绩说明会。本次年度业绩说明会将采取网 络远程的方式举行，投资者可登录"全景•路演天下（https://ir.p5w.net）参 与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：董事长管乔中先生、独立董事陈英实先 生、副总经理兼董事会秘书陈毅先生、财务总监李庆辉先生。 证券代码：300639 证券简称：凯普生物 公告编号：2023-033 广东凯普生物科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 19日（星期三）15:00前访问https://ir.p5w.net/z ...

Financial Performance - The company's operating revenue for 2022 reached ¥5,596,971,056.72, representing a 109.39% increase compared to ¥2,673,022,953.56 in 2021[22]. - Net profit attributable to shareholders was ¥1,725,459,216.97, up 102.48% from ¥852,160,115.04 in the previous year[22]. - The net cash flow from operating activities increased by 107.37% to ¥1,309,216,063.30, compared to ¥631,341,752.94 in 2021[22]. - Basic and diluted earnings per share were both ¥3.93, reflecting a 102.58% increase from ¥1.94 in 2021[22]. - Total assets at the end of 2022 amounted to ¥6,731,125,843.21, a 59.08% increase from ¥4,231,385,338.40 at the end of 2021[22]. - The company achieved operating revenue of 5,596.97 million yuan, representing a year-on-year growth of 109.39%[45]. - The net profit attributable to shareholders reached 1,725.46 million yuan, with a year-on-year increase of 102.48%[45]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1,733.94 million yuan, reflecting a growth of 106.22% year-on-year[45]. - The company achieved a total revenue of 5,596.97 million yuan in 2022, representing a year-on-year growth of 109.39%[57]. - Net profit attributable to shareholders reached 1,725.46 million yuan, an increase of 102.48% compared to the previous year[57]. Research and Development - The company reported a significant focus on research and development in molecular diagnostics, aiming to enhance its product offerings and market competitiveness[1]. - The company has invested significantly in R&D and team development to improve laboratory testing capabilities[45]. - R&D investment increased by 104.65% year-on-year, totaling 256.27 million yuan during the reporting period[77]. - The company has established multiple innovative platforms for research and development, including gene sequencing, digital PCR, and mass spectrometry technologies[78]. - The company has developed a new method for isolating trophoblast cells from pregnant women's cervical cells, which has received a patent and will be used in prenatal screening[81]. - The company is focusing on the development of genetic testing kits, including those for G6PD gene mutations, with a validity period until March 8, 2025[133]. - The company is committed to ongoing research and development to innovate and improve its diagnostic offerings[133]. - The company has received multiple patent authorizations for its HPV treatment products, which will support its growth in the HPV detection and treatment industry[125]. - The company has established partnerships with several research institutions to enhance its R&D capabilities and product offerings[130]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies to increase its footprint in the biotechnology sector[1]. - The company aims to maximize market expansion for HPV testing products, leveraging national screening initiatives[58]. - The company is strategically positioning itself in the market by enhancing its product offerings and expanding its technological capabilities[136]. - The company is focusing on expanding its international business and developing detection products suitable for various countries and regions[185]. - The company is leveraging national health policies to target areas such as maternal and child health, birth defects, and early cancer screening, enhancing its product development and market expansion efforts[175]. - The company plans to expand its third-party medical laboratory network, with 36 laboratories expected to be operational in 2023, enhancing its position in the medical testing industry[195]. Product Development and Offerings - The company has developed a complete range of HPV testing products, with over 50 million HPV screenings conducted, and is recognized as a pioneer in cervical cancer screening in China[39]. - The company has launched a multi-level product matrix in STD testing, including the first domestic ten-pathogen simultaneous detection kit, enhancing its product offerings in infectious disease diagnostics[40]. - The company is developing clinical application test kits based on tandem mass spectrometry technology, targeting various metabolic substances for disease detection, which is expected to expand reagent sales and increase business revenue[125]. - The company has developed a series of nucleic acid testing products for cervical cancer, thalassemia, and other genetic diseases, with over 100 patents granted[99]. - The company is in the production phase for a reference product for HPV gene testing, aimed at solidifying its leading position in the HPV detection market[126]. - The company is focusing on enhancing its product offerings in the field of nucleic acid testing, which is critical for clinical diagnostics[135]. Compliance and Quality Control - The company has maintained a consistent financial reporting process, ensuring accuracy and completeness in its annual report[3]. - The company has implemented a full-process quality control management system to ensure product quality from raw material procurement to after-sales service[106]. - The company has achieved ISO13485 and ISO9001 certifications, enhancing its quality management system and optimizing resource allocation for audits[86]. - The company’s third-party medical laboratories have been certified under ISO15189, ensuring compliance with international quality management standards[87]. - The company maintained a 100% compliance rate for positive sample retesting during the COVID-19 pandemic, demonstrating rigorous quality control measures[88]. Operational Risks and Challenges - Future operational risks have been identified, and the company emphasizes the importance of investor awareness regarding these risks[3]. - The company is facing regulatory risks due to ongoing changes in industry policies and regulations, which could impact its operations if compliance is not met[200]. - The company has established strict production and management systems to mitigate potential regulatory risks and ensure compliance with industry laws[200]. Investments and Financial Management - The total investment amount for the reporting period reached CNY 196,653,699, representing a significant increase of 154.73% compared to CNY 77,200,000 in the same period last year[154]. - The company has committed to invest RMB 102.74196 million in various projects, with a cumulative investment of RMB 644.6456 million as of the reporting period[162]. - The total planned investment for the nucleic acid molecular diagnostic product industrialization project is CNY 136.23 million, with an actual investment of CNY 113.65 million, accounting for 83.42% of the planned investment[164]. - The company has not reported any significant changes in the effectiveness of the projects funded by the raised capital[162]. Corporate Social Responsibility - The company donated RMB 10 million annually to the Guangdong Provincial Basic and Applied Basic Research Fund, totaling RMB 30 million from 2021 to 2023, supporting research in public health and precision medicine[80]. - The company has established and is promoting the "Meizhou Thalassemia Prevention Model" and "Foshan Hearing Loss Gene Prevention Model" nationwide, and is developing the "Chaozhou Birth Defect Prevention Model"[199]. - The Jiangxi Provincial Government announced free prenatal and newborn disease screenings, which the company aims to leverage for growth through its advanced technology and professional services[199].

证券代码：300639 证券简称：凯普生物 广东凯普生物科技股份有限公司投资者关系活动记录表 编号：2019001 | --- | --- | --- | |-----------------------|-------------------------------------------------------------------------|-----------------------------------------------------------| | 投资者关系 \n活动类别 | █ \n□媒体采访 □业绩说明会 \n□ 新闻发布会 □路演活动 \n█现场参观 \n□ 其他 | 特定对象调研 □分析师会议 | | 参与单位名称及 | | 方正证券股份有限公司 周小刚、陈家华；广州广证恒生证券研究 | | 人员姓名（排名 | | 所有限公司 唐爱金、谭紫媚；广发证券股份有限公司 吴文华； | | 不分先后） | | | | | | 安信证券股份有限公司 陈嘉文；天风证券股份有限公司 李扬； | | | | 长江证券股份有限公司 王琰；金元证券股份有限公司 蒋贻伶； | | | | 万联证 ...

证券代码：300639 证券简称：凯普生物 广东凯普生物科技股份有限公司投资者关系活动记录表 编号：2018001 | --- | --- | --- | --- | |-----------------------|----------------------------|-------------------------------------------------------------------------|----------------------------------------------------| | 投资者关系 \n活动类别 | █ \n□ \n█现场参观 \n□ 其他 | 特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n新闻发布会 □路演活动 | | | 参与单位名称及 | 东北证券：崔洁铭、齐震 | | | | 人员姓名 | | | | | 时间 | 2018 年 4 月 12 | 日上午 10:00-11:30 | | | | | | | | 地点 | | 广州市黄埔区中新知识城凤凰三横路 71 | 号公司七楼会议室 | | 上市公司接待 人员姓名 | 副总经 ...

证券代码：300639 证券简称：凯普生物 广东凯普生物科技股份有限公司投资者关系活动记录表 编号：2018002 | --- | --- | --- | |-----------------------------|---------------------------------------------|----------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | | □媒体采访 █业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | 活动类别 | █现场参观 | | | | □ 其他 | | | 会议主题 | 2018 | 年中期业绩说明会暨投资者交流活动 | | 时间 | 2018 年 8 月 17 | 日 14:30-17:30 | | | | | | 地点 | | 广州市黄埔区中新知识城凤凰三横路 71 号公司八楼会议室 | | 上市公司接待 | 董事、总经理：管乔中 董事、副总经理：管秩生 | | | 人员姓名 | 副总经理：谢龙旭 | | | | 财务总监：李 ...

证券代码：300639 证券简称：凯普生物 编号：2020002 | --- | --- | --- | |---------------------------|------------------------|----------------------------------------------------------| | | █ | 特定对象调研 █分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | 活动类别 | █现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 招商局资本投资有限责任公司（张冬雪）、华菱津杉（天津）产 | | 人员姓名（排名 不分先后） | | 业投资管理有限公司（张擎柱）、广证恒生证券研究所（唐爱 | | | | 金）、太平洋证券股份有限公司（谭紫媚）、国泰基金管理有限 | | | | 公司（刘杨阳）、浙商证券股份有限公司（高超）、华泰柏瑞基 | | | | 金管理有限公司（谢峰）、中泰证券股份有限公司（谢木青）、 | | | | 华夏基金管理有限公司（罗鸣）、国海富兰克林基金管理有限公 ...

证券代码：300639 证券简称：凯普生物 广东凯普生物科技股份有限公司投资者关系活动记录表 编号：2020003 | --- | --- | --- | --- | |-------------------------------------|-----------|--------------------------|--------------------------------------------------------------| | | | | | | | █ | 特定对象调研 □分析师会议 | | | | | □媒体采访 □业绩说明会 | | | 投资者关系 | □ | 新闻发布会 █路演活动 | | | 活动类别 | □现场参观 | | | | | □ 其他 | | | | 主要参与单位名 | | | 招商资本（王荣）、国寿安保基金（刘志军）、建银国际（林雷、金 | | | | | | | 称 及 人 员 姓 名 （ 排 名 不 分 先 | | | 石轩、罗丽、袁亮）、朱雀基金（李扬、周鸣杰）、中银基金（王方 | | 后） | | | 舟）、贝莱德基金（秦瑶函）、前海人寿（王安艺）、景泰 ...

证券代码：300639 证券简称：凯普生物 1 / 6 广东凯普生物科技股份有限公司投资者关系活动记录表 编号：2021002 | --- | --- | --- | |-------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 | □分析师会议 | | 投资者关系 | | □媒体采访 □业绩说明会 □新闻发布会 □路演活动 | | 活动类别 | □现场参观 | | | | ☑ 其他 电话调研 富国基金 毕天宇 | 郭舒洁；新华基金 赵强；方正证 ...

证券代码：300639 证券简称：凯普生物 编号：2022003 广东凯普生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------------------------------------------|------------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □新闻发布会 | 路演活动 | | 类别 | □现场参观 | | | | ☑ 其他 （ 2022 活动） | 年广东辖区上市公司投资者网上集体接待日 | | 参与单位名称及 人员姓名 | 通过全景网"投资者关系互动平台"（ 参与 2022 的投资者 | https://ir.p5w.net ） 年广东辖区上市公司投资者网上集体接待日活动 | | 时间 | 2022 年 9 月 22 日 15:50-16:50 | | | | | | | 地点 ...